Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181) A/TEXAS/50/2012 (H3N2) DERIVED STRAIN USED (NYMC X-233A) B/MASSACHUSETTS/2/2012-LIKE STRAIN USED B/MASSACHUSETTS/2/2012 WILD TYPE
Novartis Vaccines and Diagnostics S.r.l.
A/CALIFORNIA/7/2009 (H1N1)PDM09-DERIVED STRAIN USED (NYMC X-181) A/TEXAS/50/2012 (H3N2) DERIVED STRAIN USED (NYMC X-233A) B/MAS
0.5
Suspension for Injection
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
PACKAGE LEAFLET: INFORMATION FOR THE USER FLUAD ® 2014/2015, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Influenza vaccine surface antigen, inactivated, adjuvanted with MF59C.1 READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU RECEIVE THIS VACCINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This vaccine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If you get any side effects. talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS INTHIS LEAFLET: 1. What Fluad is and what is it used for 2. What you need to know before you use Fluad 3. How to use Fluad 4. Possible side effects 5. How to store Fluad 6. Contents of the pack and other information 1. WHAT FLUAD IS AND WHAT IS IT USED FOR Fluad is a vaccine. This vaccine helps to protect you against influenza (flu). It is used as active immunisation in the elderly (of 65 years of age and over), particularly in people with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases). Fluad should be used in accordance with the official recommendations. Through vaccination with Fluad, the immune system (the body’s natural defence system) is stimulated to produce its own protection (antibodies) against the illness. None of the ingredients of this vaccine can by itself cause flu. Flu is a disease that can spread rapidly and is caused by different types of strains that can change every year. Therefore, this is why you might need t Прочетете целия документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fluad, suspension for injection in pre-filled syringe Influenza Vaccine, Surface Antigen, Inactivated, Adjuvanted with MF59C.1 (2014/2015 SEASON) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus surface antigens (haemagglutinin and neuraminidase), of strains*: A/California/7/2009 (H1N1)pdm09 – derived strain used (NYMC X-181) 15 micrograms HA** A/Texas/50/2012 (H3N2) – derived strain used (NYMC X-223) 15 micrograms HA** B/Massachusetts/2/2012 – (wild type) 15 micrograms HA** *propagated in eggs and adjuvanted with MF59C.1 **haemagglutinin Adjuvant: MF59C.1 which is an exclusive adjuvant: 9.75 mg squalene, 1.175 mg polysorbate 80, 1.175 mg sorbitan trioleate, 0.66 mg sodium citrate, 0.04 mg citric acid, water for injections. For one dose of 0.5 ml This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2014/2015 season. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. The vaccine appears as a milky-white suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Active immunisation against influenza in the elderly (65 years of age and over), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases). The use of FLUAD should be based on official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION A single 0.5 ml dose should be administered by intramuscular injection into the deltoid muscle. Due to the presence of the adjuvant, the injection should be carried out by using a 1 inch needle. For instructions for preparation, see section 6.6. HEALTH PRODUCTS REGULATORY AUTHORITY Прочетете целия документ